Drugs in Dev. Pulmonary/Respiratory Diseases
Phase I
Iceland 
Lead Product(s) : EP395
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Commencement of LPS Challenge Trial for Lead Candidate EP395
Details : EP395 is an orally available macrolide or ‘Barriolide™‘ with reduced antimicrobial activity which aims to address the unmet medical need for a treatment for COPD (Chronic Obstructive Pulmonary Disease).
Product Name : EP395
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 31, 2022
Lead Product(s) : EP395
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EP395
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Successful Completion of Phase I Study for Lead Asset EP395
Details : EP395, is the first of EpiEndo’s orally available, non-antibiotic macrolides or ‘Barriolides™’, to enter clinical development and will be targeting chronic obstructive pulmonary disease (COPD).
Product Name : EP395
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 18, 2022
Lead Product(s) : EP395
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EP395
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Flerie Invest
Deal Size : $23.6 million
Deal Type : Series A Financing
Details : The financing secures funds to advance clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication.
Product Name : EP395
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 18, 2021
Lead Product(s) : EP395
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Flerie Invest
Deal Size : $23.6 million
Deal Type : Series A Financing
Reset All
